Details

Autor(en) / Beteiligte

• Sekiguchi, Yasunobu
• Shimada, Asami
• Matsuzawa, Moe
• Imai, Hidenori
• Wakabayashi, Mutsumi
• Sugimoto, Keiji
• Nakamura, Noriko
• Sawada, Tomohiro
• Arita, Junichi
• Komatsu, Norio
• Noguchi, Masaaki

Titel

Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature

Ist Teil von

• Turkish journal of haematology, 2015-09, Vol.32 (3), p.257-262

Ort / Verlag

Turkey: Galenos Publishing

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• The patient, a 79-year-old Japanese man, was diagnosed with the chronic phase of chronic myeloid leukemia and begun on nilotinib therapy in April 2011. The therapeutic response was major molecular response in August. About 19 months after the start of nilotinib therapy at 400 mg/day (November 2012), an adenocarcinoma (24 x 20 mm) confined to the head of the pancreas developed. In February 2013, a pancreaticoduodenectomy was performed. The therapy regimen was switched to dasatinib at 100 mg/day, beginning in April. The response was still major molecular response with no recurrence of pancreatic carcinoma in July 2013. There have been 29 reported cases of secondary neoplasms associated with nilotinib therapy. These secondary neoplasms were characterized by relatively frequent occurrence of papilloma (6 cases), gastric cancer (3 cases), fibroma (3 cases), and thyroid neoplasms (2 cases). The present case, however, is the first to be reported as carcinoma of the pancreas. This report describes the case.